

## Preliminary program

### 8th Halle Conference on Recombinant Proteins

**Thursday, March 12<sup>th</sup>, 2026**

08.15 **Opening and Welcome**

08.30 **Plenary Lecture: *Macrophage-targeted RNA therapeutics***  
Stefan Engelhardt, TU München

#### **Session 1      Advanced molecular and cell-based therapies**

09.00 ***Receptor-targeted vectors as crucial tool for in vivo CAR T cell generation***  
Christian Buchholz, PEI Langen

09.30 ***Data-Driven Solutions for Continuous Improvement from Drug Discovery and Development to Scale-Up and Bioprocessing***  
TBD, Sartorius GmbH & Co.KG

09.45 ***Autologous & Allogeneic CAR Therapy for AML***  
Helmut Hanenberg, UK Essen

10.15 **Coffee break**

10.45 ***Early Adoption of Quality by Design: A Game Changer for Robust GMP Development: How strategic QbD integration accelerates development and minimizes risk***  
Thomas Schmid, IZI Fraunhofer Leipzig

11.15 ***Critical Quality Attributes for mRNA Therapeutics***  
Christoph Keysberg, BioNTech SE

11.45 ***Oncolytic Viruses: Applications, Development, and the Future as Advanced Therapeutic Medicinal Products (ATMPs)***  
Raphael Drerup, Boehringer Ingelheim Pharma GmbH & Co.KG

12.15 ***Pipeline und Trends zu Advanced Therapies + Wacker Innovation und Offerings***  
Christian Hundshammer, Wacker Chemie AG

12.45 **Lunch**

#### **Session 2      Peptide-based therapies and scaffold proteins**

13.45 ***Designed cyclic peptides as multifunctional inhibitors of pathogenic amyloid self-assembly***  
Aphrodite Kapurniotu, TU München

14.15 ***A new era of chemical peptide manufacturing***  
Günther Loidl, Bachem AG

14.45 ***Pure & Precision – The Navigo Proteins Spectrum***

Henning Afflerbach, Navigo Proteins GmbH

**Session 3      New platforms for analytics and therapeutic development**

15.00 ***Biophysics in Antibody Development***

Vera Molkenhain, 2bind GmbH

15.30 ***Exploring cellular organization in native cell extracts with high-resolution cryo-EM***

Panagiotis Kastiris, Martin-Luther-University Halle Wittenberg

**16.00 Coffee break**

16.30 ***Tackling new challenges in molecular interaction analysis: from small molecules to cells***

Ralf Strasser, Bruker Biosensors

16.45 Dieter Heindl, Roche Diagnostics GmbH

17.15 ***To platform or not to platform: strategic considerations for antibody formulation in early clinical development***

Tim Menzen, Coriolis Pharma Research GmbH

17.45 ***Preclinics, protein engineering technology and host strains***

Valentina Garrapa, Preclinics GmbH

18.00 **Evening reception** including Poster session and Industry exhibition

22.00 Ending

**Friday, March 13<sup>th</sup>, 2026**

08.30 **Plenary Lecture: *Developing therapeutic bispecific antibodies for oncology and beyond***

Christian Klein, Ludwig-Maximilians-University München

**Session 4      Antibodies and beyond**

09.00 ***Beyond T Cell Engager - Novel NK Cell Engager for Leukemia and Myeloma Therapy***

Katja Klausz, UKSH Kiel

09.30 ***Pioneering BsAb Production with High-Throughput Platforms and Fit-for-Need Analytical Solutions***

Winfried Elis, WuXI Biologics Germany GmbH

10.00 (Vorstellung Phage Display Antikörpergenerierungs-Plattform)

Francisco Ylera, Bio-Rad AbD Serotec GmbH

**10.15 Coffee break**

10.45 ***Selection of antibodies against integral membrane proteins***  
Konstantin Hinnah, Max-Planck-Institute Heidelberg

11.15 Startup Elevator, eversyn GmbH, matrihealth GmbH

11.45 ***Nanobody-based synthetic cytokine receptors***  
Doreen Floss, Heinrich-Heine-University Düsseldorf

**12.15 Lunch**

13.15 **The evolution of mAb's requiring more niche solutions to meet Today's demands for Process Intensification**  
Henrik Ihre, Cytiva Europe GmbH

13.45 ***Molecular engineering of immune proteins***  
Matthias Feige, TU München

14.15 ***Generation and Engineering of Bi-and Multifunctional Antibody Derivatives for Immunomodulation***  
Stefan Zielonka, Merck Healthcare KGaA & TU Darmstadt

14.45 **Closing remarks**

- Subject to change -